NCT00254254 - A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Exenatide - Exenatide - Placebo

Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose, followed by placebo 0.02 mL, single dose. All are subcutaneous injections.

DRUG

Exenatide - Placebo - Exenatide

Exenatide 2.5 mcg, single dose, followed by placebo 0.02 mL, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.

DRUG

Placebo - Exenatide - Exenatide

Placebo 0.02 mL, single dose, followed by Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.

Trial Locations (5)

Research Site, Little Rock

Research Site, San Diego

Research Site, Denver

Research Site, Louisville

Research Site, San Antonio